6.01 USD
+0.01
0.17%
At close Apr 21, 4:00 PM EDT
After hours
6.00
-0.01
0.17%
1 day
0.17%
5 days
0.17%
1 month
-20.92%
3 months
-31.78%
6 months
-40.73%
Year to date
-29.87%
1 year
47.67%
5 years
-72.09%
10 years
-96.43%
 

About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Employees: 1,992

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]

44% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 54

5.49% more ownership

Funds ownership: 58.55% [Q3] → 64.04% (+5.49%) [Q4]

5% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 41

3% less funds holding

Funds holding: 233 [Q3] → 226 (-7) [Q4]

29% less call options, than puts

Call options by funds: $65.9M | Put options by funds: $92.9M

30% less capital invested

Capital invested by funds: $1.19B [Q3] → $825M (-$361M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for NVAX.

Financial journalist opinion

Based on 20 articles about NVAX published over the past 30 days

Positive
Zacks Investment Research
7 hours ago
Why the Market Dipped But Novavax (NVAX) Gained Today
Novavax (NVAX) closed at $6.01 in the latest trading session, marking a +0.17% move from the prior day.
Why the Market Dipped But Novavax (NVAX) Gained Today
Negative
Zacks Investment Research
6 days ago
Here's Why Novavax (NVAX) Fell More Than Broader Market
In the latest trading session, Novavax (NVAX) closed at $6.39, marking a -0.31% move from the previous day.
Here's Why Novavax (NVAX) Fell More Than Broader Market
Neutral
PRNewsWire
6 days ago
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA
Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccine Full results will be submitted for publication later this year GAITHERSBURG, Md. , April 15, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preliminary results from the SHIELD-Utah study (Study of Healthcare Workers and First Responders Investigating Effects of Systemic and Local reactogenicity of COVID-19 Vaccine Doses in Utah) that showed Novavax's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) targeting the JN.1 strain resulted in fewer and less severe reactogenicity symptoms, when compared with the Pfizer-BioNTech mRNA 2024-2025 vaccine.
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA
Negative
Zacks Investment Research
1 week ago
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab
The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 vaccine in a recent interview.
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab
Positive
Zacks Investment Research
1 week ago
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Negative
Reuters
1 week ago
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy
Vaccine maker Novavax's shares plunged over 22% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID-19 vaccine in an interview with CBS News.
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy
Positive
Zacks Investment Research
1 week ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Positive
The Motley Fool
1 week ago
2 Beaten-Down Stocks That Still Aren't Worth Buying
President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for investors to look for bargains.
2 Beaten-Down Stocks That Still Aren't Worth Buying
Positive
Zacks Investment Research
2 weeks ago
Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?
Negative
Zacks Investment Research
2 weeks ago
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $5.98, marking a -0.33% move from the previous day.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Charts implemented using Lightweight Charts™